Hypermethylated promoter region of DR3, the death receptor 3 gene, in rheumatoid arthritis synovial cells

Arthritis and Rheumatism

Volumn 54, Issue 3, 2006, Pages 779-787

  Takami, Nozomi ^a   Osawa, Kayo ^a   Miura, Yasushi ^b   Komai, Koichiro ^a   Taniguchi, Mariko ^a   Shiraishi, Masahiko ^c   Sato, Keizo ^d   Iguchi, Tetsuhiro ^d   Shiozawa, Kazuko ^e   Hashiramoto, Akira ^b   Shiozawa, Shunichi ^a  

^a KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KOBE UNIVERSITY HOSPITAL   (Japan)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^d KOBE ROSAI HOSPITAL   (Japan)

^e Konan Kakogawa Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL METHYLASE SSS I; BISULFITE; DEATH RECEPTOR; DEATH RECEPTOR 3; GENOMIC DNA; LUCIFERASE; METHYLTRANSFERASE; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; DR3 GENE; FEMALE; GENE; GENE EXPRESSION; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; OSTEOARTHRITIS; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SEQUENCE ALIGNMENT; SYNOVIOCYTE; TRANSACTIVATION; WESTERN BLOTTING;

ADULT; AGED; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MALE; METHYLATION; MIDDLE AGED; OSTEOARTHRITIS; PROMOTER REGIONS (GENETICS); RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 25; SYNOVIAL MEMBRANE;

EID: 33644890154     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21637     Document Type: Article

References (38)

1. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16.
2. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2004;350:2167-79.
3. Russell JH, Rush B, Weaver C, Wang R. Mature T cells autoimmune lpr/lpr mice have a defect in antigen-stimulated suicide. Proc Natl Acad Sci U S A 1993;90:4409-13.
4. Singer GG, Abbas AK. The Fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity 1994;1:365-71.
5. Rathmell JC, Townsend SE, Xu JC, Flavell RA, Goodnow CC. Expansion or elimination of B cells in vivo: dual roles for CD40-and Fas (CD95)-ligands modulated by the B cell antigen receptor. Cell 1996;87:319-29.
6. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992;356:314-7.
7. Adachi M, Watanabe-Fukunaga R, Nagata S. Aberrant transcription caused by the insertion of an early transposable element in an intron of the Fas antigen gene of lpr mice. Proc Natl Acad Sci U S A 1993;90:1756-60.
8. Takahashi T, Tanaka M, Brannan CI, Jenkins NA, Copeland NG, Suda T, et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994;76:969-76.
9. Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middleton LA, Lin AY, et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995;81:935-46.
10. Wu J, Wilson J, He J, Xiang L, Schur PH, Mountz JD. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest 1996;98:1107-13.
11. Ichikawa K, Liu W, Fleck M, Zhang H, Zhao L, Ohtsuka T, et al. TRAIL-R2 (DR5) mediates apoptosis of synovial fibroblasts in rheumatoid arthritis. J Immunol 2003;171:1061-9.
12. Marsters SA, Sheridan JP, Donahue CJ, Pitti RM, Gray CL, Goddard AD, et al. Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-κB. Curr Biol 1996;6:1669-76.
13. Kitson J, Raven T, Jiang YP, Goeddel DV, Giles KM, Pun KT, et al. A death-domain-containing receptor that mediates apoptosis. Nature 1996;384:372-5.
14. Chinnaiyan AM, O'Rourke K, Yu GL, Lyons RH, Garg M, Duan DR, et al. Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science 1996;274:990-2.
15. Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 1989;169:1747-56.
16. Trauth BC, Klas C, Peters AM, Matzku S, Moller P, Falk W, et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989;245:301-5.
17. Briggs MR, Kadonaga JT, Bell SP, Tjian R. Purification and biochemical characterization of the promoter-specific transcription factor, Sp1. Science 1986;234:47-52.
18. Saffer JD, Jackson SP, Annarella MB. Developmental expression of Sp1 in the mouse. Mol Cell Biol 1991;11:2189-99.
19. Jones PA. Cancer: death and methylation. Nature 2001;409:143-4.
20. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
21. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum 1986;29:1039-49.
22. Hashiramoto A, Sano H, Maekawa T, Kawahito Y, Kimura S, Kusaka Y, et al. c-myc antisense oligodeoxynucleotides can induce apoptosis and down-regulate Fas expression in rheumatoid synoviocytes. Arthritis Rheum 1999;42:954-62.
23. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996;93:9821-6.
24. Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW, et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci U S A 1992;89:1827-31.
25. Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics 2002;18:1427-31.
26. Deng G, Chen A, Hong J, Chae HS, Kim YS. Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression. Cancer Res 1999;59:2029-33.
27. Kawasaki H, Komai K, Nakamura M, Yamamoto E, Ouyang Z, Nakashima T, et al. Human weel kinase is directly transactivated by and increased in association with c-Fos/AP-1: rheumatoid synovial cells overexpressing these genes go into aberrant mitosis. Oncogene 2003;22:6839-44.
28. 1/S to inhibit premature mitosis in antigen-specific Th1 cells. EMBO J 2001;20:4618-27.
29. Rudert F, Visser E, Forbes L, Lindridge E, Wang Y, Watson J. Identification of a silencer, enhancer, and basal promoter region in the human CD95 (Fas/APO-1) gene. DNA Cell Biol 1995;11:931-7.
30. Esteller M, Herman JG. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol 2002;196:1-7.
31. Petak I, Danam RP, Tillman DM, Vernes R, Howell SR, Berczi L, et al. Hypermethylation of the gene promoter and enhancer region can regulate Fas expression and sensitivity in colon carcinoma. Cell Death Differ 2003;10:211-7.
32. Suske G. The Sp-family of transcription factors. Gene 1999;238:291-300.
33. Jones AP, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-28.
34. Hermann A, Gowher H, Jeltsch A. Biochemistry and biology of mammalian DNA methyltransferases. Cell Mol Life Sci 2004;61:2571-87.
35. Migone TS, Zhang J, Luo X, Zhuang L, Chen C, Hu B, et al. TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 2002;16:479-92.
36. Shimizu M, Miura Y, Hashiramoto A, Shimizu T, Murao H, Shiozawa S. TL1A, a specific ligand for death receptor 3 and agonistic anti-DR3 antibody, inhibit type II collagen-induced arthritis in mice [abstract]. Arthritis Rheum 2004;50 Suppl 9:S569.
37. Baier A, Meineckel I, Gay S, Pap T. Apoptosis in rheumatoid arthritis. Curr Opin Rheumatol 2003;15:274-9.
38. Nakajima T, Aono H, Hasunuma T, Yamamoto K, Shirai T, Hirohata K, et al. Apoptosis and functional Fas antigen in rheumatoid arthritis synoviocytes. Arthritis Rheum 1995;38:485-91.